Paritaprevir
CAS: 1216941-48-8
Ref. 3D-AP178043
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
- (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
- Abt 450
- Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-
- ABT450
Paritaprevir is an inhibitor drug that is used in the treatment of hepatitis C. It binds to the active site of the viral polymerase and blocks viral RNA synthesis. Paritaprevir has a half-life of about 3 hours and a concentration-time curve that results in an interactive response with wild-type virus, which may lead to antiviral resistance. Paritaprevir has been shown to be effective for patients with hepatic impairment, but it is not recommended for patients who are obese or have a body mass index greater than 30 kg/m2 because these conditions can increase the risk of adverse effects.
Propiedades químicas
Consulta técnica sobre: 3D-AP178043 Paritaprevir
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
